Clinical Trial Update: Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update: venetoclax plus ASTX727 is being studied for relapsed, refractory, or newly diagnosed acute myeloid leukemia and is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING